Literature DB >> 35286515

Dose-Dependent Effects of Astaxanthin on Ischemia/Reperfusion Induced Brain Injury in MCAO Model Rat.

Forough Taheri1,2, Ehsan Sattari1, Maryam Hormozi1, Hassan Ahmadvand2,3, Mohammad Reza Bigdeli4, Parastou Kordestani-Moghadam1, Khatereh Anbari5, Sara Milanizadeh4, Mehrnoush Moghaddasi6,7.   

Abstract

Excitotoxicity and oxidative stress are central to the pathology of the nervous system, and inhibition of excitotoxicity induced by glutamate is one of the therapeutic goals determined for stroke. The present study aimed to investigate the effects of Astaxanthin, a potent natural antioxidant, on complications caused by acute cerebral stroke. In this research, 60 male Wistar rats were used which were divided into 5 groups as follow: (1) the sham group (vehicle), (2) the ischemic control group (vehicle), and the ischemic groups treated by Astaxanthin with doses of 25, 45, and 65 mg/kg. In the ischemic groups, ischemic model was performed by middle cerebral artery occlusion (MCAO) method, and the Astaxanthin administration was carried out after the artery occlusion and before opening the artery. The obtained results indicated that Astaxanthin could significantly reduce stroke volume, neurological deficits, and lipid peroxidation. Moreover, it was able to restore total oxidant status (TOS) and caspase 3 level to the normal level. The activity of antioxidant enzyme glutathione peroxidase (GPX), and the expression of catalase, GPx and nuclear factor kappa B (NFκb) genes, which were reduced after ischemia, were increased. This phenomenon was particularly pronounced for glutamate transporter 1 (GLT-1). Furthermore, Astaxanthin decreased the augmented pro-apoptotic gene Bax and restored the reduced Bcl2 expression to the normal level. Significant effects on the P53 and PUMA expression were not observed. Overall, the medium dosage of Astaxanthin appears to be more effective in reducing the complications of ischemia, particularly on our major study endpoints (stroke volume and neurological defects). Longer studies with a more frequent administration of Astaxanthin are required to better understand the precise mechanism of Astaxanthin.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Astaxanthin; Gene expression; Glutamate transporter; Middle cerebral artery occlusion; Neurological deficit; Stroke

Mesh:

Substances:

Year:  2022        PMID: 35286515     DOI: 10.1007/s11064-022-03565-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  56 in total

Review 1.  Pathobiology of ischaemic stroke: an integrated view.

Authors:  U Dirnagl; C Iadecola; M A Moskowitz
Journal:  Trends Neurosci       Date:  1999-09       Impact factor: 13.837

Review 2.  Neuronal life and death: an essential role for the p53 family.

Authors:  F D Miller; C D Pozniak; G S Walsh
Journal:  Cell Death Differ       Date:  2000-10       Impact factor: 15.828

3.  p53 opens the mitochondrial permeability transition pore to trigger necrosis.

Authors:  Angelina V Vaseva; Natalie D Marchenko; Kyungmin Ji; Stella E Tsirka; Sonja Holzmann; Ute M Moll
Journal:  Cell       Date:  2012-06-22       Impact factor: 41.582

Review 4.  Apoptotic cell death regulation in neurons.

Authors:  Emilie Hollville; Selena E Romero; Mohanish Deshmukh
Journal:  FEBS J       Date:  2019-07-12       Impact factor: 5.542

5.  Preventive treatment of astaxanthin provides neuroprotection through suppression of reactive oxygen species and activation of antioxidant defense pathway after stroke in rats.

Authors:  Lei Pan; Ying Zhou; Xiu-Fang Li; Qing-Jia Wan; Le-Hua Yu
Journal:  Brain Res Bull       Date:  2017-02-01       Impact factor: 4.077

Review 6.  Apoptosis regulation in the penumbra after ischemic stroke: expression of pro- and antiapoptotic proteins.

Authors:  Anatoly B Uzdensky
Journal:  Apoptosis       Date:  2019-10       Impact factor: 4.677

Review 7.  GLT-1 Upregulation as a Potential Therapeutic Target for Ischemic Brain Injury.

Authors:  Yu-Yan Hu; Li Li; Xiao-Hui Xian; Min Zhang; Xiao-Cai Sun; Shu-Qin Li; Xin Cui; Jie Qi; Wen-Bin Li
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

8.  Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association.

Authors:  Bruce Ovbiagele; Larry B Goldstein; Randall T Higashida; Virginia J Howard; S Claiborne Johnston; Olga A Khavjou; Daniel T Lackland; Judith H Lichtman; Stephanie Mohl; Ralph L Sacco; Jeffrey L Saver; Justin G Trogdon
Journal:  Stroke       Date:  2013-05-22       Impact factor: 7.914

9.  Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke.

Authors:  Brandon K Harvey; Mikko Airavaara; Jason Hinzman; Emily M Wires; Matthew J Chiocco; Douglas B Howard; Hui Shen; Greg Gerhardt; Barry J Hoffer; Yun Wang
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

Review 10.  Nutraceutical antioxidants as novel neuroprotective agents.

Authors:  Natalie A Kelsey; Heather M Wilkins; Daniel A Linseman
Journal:  Molecules       Date:  2010-11-03       Impact factor: 4.411

View more
  1 in total

1.  Astaxanthin Confers a Significant Attenuation of Hippocampal Neuronal Loss Induced by Severe Ischemia-Reperfusion Injury in Gerbils by Reducing Oxidative Stress.

Authors:  Joon Ha Park; Tae-Kyeong Lee; Dae Won Kim; Ji Hyeon Ahn; Choong-Hyun Lee; Jong-Dai Kim; Myoung Cheol Shin; Jun Hwi Cho; Jae-Chul Lee; Moo-Ho Won; Soo Young Choi
Journal:  Mar Drugs       Date:  2022-04-14       Impact factor: 6.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.